Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	941.71	418.41	851.03	604.07	1,521	199.41
Short-Term Investments	1,834	1,737	1,694	2,339	1,951	144.28
Trading Asset Securities	20.2	0.24	174.37	232.19	53.4	10.39
Cash & Short-Term Investments	2,796	2,156	2,719	3,175	3,525	354.08
Cash Growth	8.52%	-20.73%	-14.37%	-9.91%	895.41%	-29.04%
Accounts Receivable	102.73	63.73	27.97	0.48	10.55	-
Other Receivables	50.32	51.02	18.5	34.01	0.72	0.84
Receivables	153.05	114.75	46.47	34.49	11.27	0.84
Inventory	169.13	123.97	61.1	51.33	22.43	11.33
Prepaid Expenses	13.04	-	-	-	-	-
Restricted Cash	-	-	1.78	-	-	-
Other Current Assets	46.93	71.7	111	48.83	23.67	14.66
Total Current Assets	3,178	2,466	2,940	3,310	3,582	380.92
Property, Plant & Equipment	1,107	1,048	893.74	584.43	177.53	124.82
Long-Term Investments	280.4	210.03	21.63	20.57	20.28	-
Other Intangible Assets	8.61	9.75	1.11	1.5	1.1	0.11
Other Long-Term Assets	56.49	32.66	26.91	15.84	153.59	24.1
Total Assets	4,631	3,767	3,883	3,932	3,934	529.95
Accounts Payable	49.27	26.01	29.49	14.91	2.78	3.42
Accrued Expenses	130.22	118.39	113.2	90.99	49.93	15.31
Short-Term Debt	401.84	337.18	13.01	60.79	0.55	42.37
Current Portion of Long-Term Debt	145.93	135.19	32.81	0.6	-	-
Current Portion of Leases	11.49	12.36	19.43	11.08	11.72	4.18
Current Income Taxes Payable	2.01	4.97	1.82	1.03	0.94	0.16
Current Unearned Revenue	0.45	1.58	-	-	1.61	10.87
Other Current Liabilities	64.13	112.05	104.42	200.3	44.54	3.93
Total Current Liabilities	805.34	747.73	314.18	379.7	112.08	80.24
Long-Term Debt	299.5	257.19	331.83	28.8	-	1,386
Long-Term Leases	13.54	11.32	21.62	20.93	26.99	20.31
Long-Term Unearned Revenue	316.93	274.78	228.19	163.67	8.72	6.79
Long-Term Deferred Tax Liabilities	0.25	0.35	0.28	-	-	-
Other Long-Term Liabilities	-	-	-	-	141.29	131.64
Total Liabilities	1,436	1,291	896.11	593.1	289.07	1,625
Common Stock	0.19	0.17	0.17	0.17	0.17	0.05
Additional Paid-In Capital	9,305	8,496	8,484	8,485	8,516	-
Retained Earnings	-6,243	-6,165	-5,649	-5,290	-4,982	-1,095
Treasury Stock	-0	-0	-	-	-	-
Comprehensive Income & Other	132.87	143.07	151.76	144.97	116.82	-
Total Common Equity	3,195	2,475	2,986	3,340	3,651	-1,095
Minority Interest	0.68	0.64	0.5	-1.07	-5.59	-0.27
Shareholders' Equity	3,195	2,475	2,987	3,339	3,645	-1,095
Total Liabilities & Equity	4,631	3,767	3,883	3,932	3,934	529.95
Total Debt	872.3	753.24	418.71	122.19	39.26	1,453
Net Cash (Debt)	1,924	1,402	2,300	3,053	3,485	-1,099
Net Cash Growth	3.85%	-39.04%	-24.65%	-12.40%	-	-
Net Cash Per Share	7.31	5.35	8.80	11.69	21.67	-16.37
Filing Date Shares Outstanding	294.6	275.6	276.6	277.39	279.74	271
Total Common Shares Outstanding	294.6	275.6	276.6	277.39	279.74	271
Working Capital	2,373	1,718	2,625	2,930	3,470	300.68
Book Value Per Share	10.84	8.98	10.80	12.04	13.05	-4.04
Tangible Book Value	3,186	2,465	2,985	3,339	3,650	-1,095
Tangible Book Value Per Share	10.81	8.94	10.79	12.04	13.05	-4.04
Buildings	-	190.16	190.16	-	-	-
Machinery	-	692.07	626.77	235.49	110.64	82.14
Construction In Progress	-	213.93	34.48	323.55	21.63	0.18
Leasehold Improvements	-	62.05	60.77	51.73	42.45	42.68

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.